M. I. Nazheva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M. I. Nazheva has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey Yur'EVich Maksimov
National Medical Research Centre for Oncology
1 shared publication - Alexandra A. Demidova
Rostov State Medical University
1 shared publication - Ekaterina V. Verenikina
National Medical Research Centre for Oncology
1 shared publication - Elena V. Bova
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
1 shared publication - I. V. Dubatova
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
1 shared publication - Mariya Yu. Grafskaya
National Medical Research Center of Oncology
1 shared publication
Latest Publications
- Open Access
- 22 September 2025
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 3,p. 24-28
Prospects for the detection of ovarian cancer by genetic testing of aspirate from the uterine cavity
In the article, a genetic study of biological samples from uterine cavity aspirate was performed in patients with serous ovarian carcinoma in order to identify gene mutations characteristic of ovarian tumor lesions. It has been proven that the aspiration from the uterine cavity contains diagnostically significant numbers of cells or fragments of ovarian cancer cells necessary for molecular genetic analysis and detection of mutations in the TP53, FAT3, CSMD3, BRAF, and KRAS genes. Mutations of the BRCA1/2 genes are rare. The detection of TP53, FAT3, CSMD3, BRAF, and KRAS gene mutations in uterine aspirate cells requires an active diagnostic search for the detection of ovarian serous carcinoma.
- 22 September 2025
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 3,p. 24-28
Open AccessProspects for the detection of ovarian cancer by genetic testing of aspirate from the uterine cavity
In the article, a genetic study of biological samples from uterine cavity aspirate was performed in patients with serous ovarian carcinoma in order to identify gene mutations characteristic of ovarian tumor lesions. It has been proven that the aspiration from the uterine cavity contains diagnostically significant numbers of cells or fragments of ovarian cancer cells necessary for molecular genetic analysis and detection of mutations in the TP53, FAT3, CSMD3, BRAF, and KRAS genes. Mutations of the BRCA1/2 genes are rare. The detection of TP53, FAT3, CSMD3, BRAF, and KRAS gene mutations in uterine aspirate cells requires an active diagnostic search for the detection of ovarian serous carcinoma.